Abstract 163P
Background
Though there are multiple drugs approved for the treatment of metastatic castration-resistant prostate cancer (CRPC), high cost can be a limiting factor in using them in a resource-limited setting. It is important to have less expensive alternatives in low-middle-income countries so that majority of the patients can have access to such a medications. We are sharing our experience in using Fosfesterol which is a cheap and orally administered estrogen analogue in metastatic CRPC.
Methods
This is a retrospective study done in a high-volume cancer center in South India. Case records of patients with CRPC who received low-dose oral Fosfestrol (120 mg three times a day) were reviewed and baseline characteristics, treatment details, outcomes, and toxicity details were recorded. Descriptive statistics were used wherever appropriate, and survival was estimated using the Kaplan Meir method.
Results
A total of 65 patients received Fosfesterol during the study period. The median age was 65 years (range 50-83 years). Thirty-four patients (53%) had other medical comorbidities.Skeletal only metastasis was commonest pattern of metastasis (n= 41,64%) followed by skeletal with nodal metastasis (n=15,23%). The majority of the patients had upfront surgical castration (n=60,93%). All the patients had adenocarcinoma and 38 patients (58%) had a high Gleason’s score (GS). Twelve patients (19%) had a GS of 7 and 5 patients (8%) had a GS of 6. GS was not available in 10 patients (15%). Forty-one patients (63%) had a PSA response (decrease of ≥50% in the PSA concentration from the baseline PSA value) and 54 patients (83%) had a symptomatic response. At the end of a median follow-up of 16 months, Median PFS was 8.3 months (CI 4.7-11.8) and the median OS was 27.5 months (CI 25.4-29.5). Twenty-nine patients (45%) received some form of subsequent treatment after stopping Fosfesterol. Most common toxicity observed was thrombosis (n=9,13%) followed by gynecomastia (n=4,6%).
Conclusions
Oral Fosfesterol is a cheap and effective agent in metastatic CRPC with a favorable toxicity profile. More studies are required to define the exact role of this drug in the management of metastatic CRPC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract